1. 1324PThe role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs). (23rd October 2018) Authors: Prinzi, N; Seregni, E; Raimondi, A; Maccauro, M; Corti, F; Lo Russo, G; Nichetti, F; Torchio, M; Coppa, J; Peverelli, G; Pagani, F; Di Bartolomeo, M; Mazzaferro, V; de Braud, F; Pusceddu, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1389PImpact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors. (23rd October 2018) Authors: Fucà, G; Poggi, M; Galli, G; Imbimbo, M; Lo Russo, G; Signorelli, D; Vitali, M; Ganzinelli, M; Zilembo, N; de Braud, F; Garassino, M C; Proto, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1419PBasal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer. (23rd October 2018) Authors: Galli, G; Poggi, M; Fucà, G; Lo Russo, G; Proto, C; Signorelli, D; Vitali, M; Ganzinelli, M; Zilembo, N; de Braud, F; Garassino, M C; Imbimbo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1466PEffects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer. (23rd October 2018) Authors: Galli, G; Poggi, M; Fucà1, G; Imbimbo, M; Proto, C; Signorelli, D; Vitali, M; Zilembo, N; Ganzinelli, M; de Braud, F; Garassino, M C; Lo Russo, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 64PEntrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. (24th November 2019) Authors: de Braud, F; Siena, S; Barlesi, F; Drilon, A; Simmons, B; Huang, X; Osborne, S; Doebele, R C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (13th August 2019) Authors: Long, G V; Flaherty, K T; Stroyakovskiy, D; Gogas, H; Levchenko, E; de Braud, F; Larkin, J; Garbe, C; Jouary, T; Hauschild, A; Chiarion-Sileni, V; Lebbe, C; Mandalá, M; Millward, M; Arance, A; Bondarenko, I; Haanen, J B A G; Hansson, J; Utikal, J; Ferraresi, V Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018) Authors: Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018) Authors: Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. (2nd July 2019) Authors: Pietrantonio, F; Lobefaro, R; Antista, M; Miceli, R; Raimondi, A; Lonardi, S; Rimassa, L; Saggio, S; Capone, I; Farina, G; Longarini, R; Mosconi, S; Bianchi, A Sartore; Tomasello, G; Petrelli, F; Murgioni, S; Perrone, F; Barault, L; Milione, M; Nicolantonio, F Di Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PD-016Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. (2nd July 2019) Authors: Raimondi, A; Di Maio, M; Peverelli, G; Morano, F; Corallo, S; Bergamo, F; Cremolini, C; Smiroldo, V; Amatu, A; Tampellini, M; Fanchini, L; Murialdo, R; Clavarezza, M; Noventa, S; Adamo, V; Ratti, M; Petrelli, F; Antonuzzo, L; Palermo, M; de Braud, F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗